Houston Myeloma Roundtable
Join us for the Houston Myeloma Roundtable at the TMC3 Collaborative Building, located at 7255 Helix Park Ave, Houston, TX, United States, on October 24th from 9:00 am-2:30 pm CT to hear from top myeloma researchers. The day includes informative and engaging presentations about the latest in myeloma as well as breakout sessions for both newly diagnosed and relapsed/refractory patients. The event will feature two sessions that include extensive Q&A. Registration and breakfast open at 8:00 am.
Meeting Details
- Meeting date: Saturday, October 24th, 2026
- Registration opens, and breakfast starts at 8:00 am; the meeting begins at 9:00 am
- Location: TMC3 Collaborative Building. 7255 Helix Park Ave, Houston, TX
- Event Rooms: Main room: Helix Hall. Meals and breakout sessions, Levy Conference Center
- Included: parking, breakfast, lunch, and refreshments
- The meeting will be recorded and available to watch at a later time
- Nearest airport: George Bush Intercontinental Airport (IAH)
Register to watch the recording
If you are unable to attend the meeting in person, we invite you to register to receive access to the recording.
Please note that this event will not be livestreamed. A recording of the program will be available approximately 1 week after the live event, and all registered individuals will receive an email with viewing instructions once it is ready.
Make it a weekend
If you are traveling to the meeting and would like to make a weekend of it while you are in Houston, here are some suggestions:
- Hotels close to the event: Blossom Hotel Houston (special rate link coming soon) and Hyatt Place Houston Medical Center
- Near three restaurants: Terrace 54, Le Petit Chef, and Potbelly
- Top three activities: Space Center Houston, The Museum of Fine Arts, and Hermann Park
Questions?
For questions about the registration, contact us at +1 800 709 1113 or email us at support@healthtree.org
To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. This helps us plan effectively and guarantees your spot at these important gatherings. If the fee is a financial burden, please reach out—we're happy to provide a promotional code to waive the cost. We appreciate your understanding and look forward to seeing you there.
- Understanding today's standard treatments for newly diagnosed myeloma, including the role of stem cell transplant.
- How immunotherapies and emerging treatments are shaping earlier lines of care
- How bispecific and trispecific antibodies work and where they fit into myeloma treatment today.
- Using antibody-drug conjugates in myeloma care.
- Who may be eligible for CAR T-cell therapy, and when it may be considered
- What patients can expect before, during, and after treatment.
Newly Diagnosed - Living Well Through Treatment: Managing Side Effects and Supportive Care, Rebecca Lu, NP
OR
Relapsed Refractory - Defining "Cure" in Myeloma: What Does It Mean Today?, Meera Mohan, MD
- How MRD, genetics, and individual patient factors help guide personalized treatment decisions.
- Using today’s expanding myeloma toolbox to build the right treatment strategy over time.
- William Matsui, MD
- Meera Mohan,MD
- Krina Patel, MD
- Rebecca Lu, NP
- Sarvari V. Yellapragada, MD
Jenny Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Krina Patel, MD, MSc
Krina Patel, MD, MSc, is Associate Professor and Center Medical Director in the Department of Lymphoma/Myeloma of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, TX. She treats only patients with plasma cell dyscrasias and is Principal Investigator for multiple ongoing phase I/II and III immune-oncology and maintenance clinical trials for myeloma patients. Her research interests include myeloma, developing cellular therapies like CAR T, and combining immunotherapy and chemotherapy in the induction, transplant, maintenance and salvage settings and she has completed significant clinical research in hematopoeitic stem cell transplantation. Dr. Patel completed her Hematology Oncology fellowship at MDACC and served as Chief Fellow. She received her MSc for a translational project she completed in the laboratory of Dr. Laurence Cooper, evaluating the combination of CAR T cells and TCR engineered cells with vaccine in in vitro and in vivo myeloma models. She served her clinical residency in internal medicine at the University of Texas UT Health in Houston, TX and earned her medical degree at the University of Texas Southwestern Medical Center in Dallas, TX.
Meera Mohan, MD, MS, FACP
Dr. Mohan completed her fellowship in Hematology Oncology training at the University of Arkansas for Medical Science. She has also worked and trained with some of the leading myeloma experts at the prestigious Myeloma Institute of Research and Therapeutics with in the University of Arkansas. She has authored and co-authored several peer reviewed publication and presented at various national and international conferences. During her fellowship she was awarded the Fellow’s Career Development Grant, Conquer Cancer American Society of Clinical Oncology (ASCO) Annual meeting merit award and Journal of Oncology Practice American Society of Oncology (ASCO) Editorial Fellowship. She received her Master’s in clinical and translational medicine (MS) from the University of Arkansas and served as a chief fellow. Her primary focus is to design and conduct clinical trials geared towards improving outcomes in Multiple Myeloma.
William Matsui, MD
William Matsui, MD is a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, where he specializes in the treatment of multiple myeloma and other plasma cell disorders. An internationally recognized physician-scientist, Dr. Matsui has spent more than two decades advancing myeloma research, with a particular focus on cancer stem cells, disease relapse, and the development of innovative immunotherapies. His clinical and research interests include stem cell transplantation, novel treatment strategies, and improving long-term outcomes for patients with multiple myeloma. He has authored more than 200 scientific publications and is a frequent speaker at national and international meetings
Rebecca Lu, RN, FNP-BC
Rebecca Lu, MSN, RN, FNP-BC, is a research nurse practitioner and Myeloma Research APRN Supervisor for the Department of Lymphoma/Myeloma at the MD Anderson Cancer Center in Houston, TX. She works intensively with myeloma patients participating in clinical trials. Ms. Lu has authored or co-authored studies on daratumumab, belantamab mafodotin, and numerous novel drug combinations. She is an active volunteer in child care and refugee assistance in Houston. Ms. Lu earned her Master of Science in Nursing from Texas A&M University in Prairie View and her nursing degree from the University of Texas at Arlington.
Sarvari Yellapragada, MD
Sarvari Yellapragada, MD is a Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, where she specializes in the treatment of multiple myeloma and other plasma cell disorders. She has extensive experience caring for patients across the spectrum of myeloma, with a focus on personalized treatment strategies, novel therapies, and improving long-term patient outcomes. Dr. Yellapragada is actively involved in clinical research evaluating emerging therapies and expanding access to innovative treatment approaches for patients with multiple myeloma.